NCT03746522View on ClinicalTrials.gov

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 23, 2018

Primary Completion Date

November 16, 2020

Study Completion Date

March 8, 2021

Conditions
Bardet Biedl Syndrome (BBS)Alström Syndrome (AS)
Interventions
DRUG

Setmelanotide

SC injection of setmelanotide

DRUG

Placebo

SC injection of placebo

Trial Locations (12)

10032

Columbia University Center, New York

27612

M3 Wake Research, Raleigh

28009

Universidad Autónoma de Madrid University Hospital Niño, Madrid

38103

University of Tennessee Health Science Center, Memphis

54449

Marshfield Clinic Research Foundation, Marshfield

67091

Centre Hospitalier Universitaire de Strasbourg, Strasbourg

75013

Sorbonne University, Hôpital de la Pitié-Salpêtrière, Paris

92108

Wr-McCr, Llc, San Diego

01199

UMMS Baystate Health; BAYSTATE MEDICAL CENTER; Baystate Children's Specialty Center, Springfield

T6G 2E1

Alberta Health Services, Edmonton

00935

UPR Medical Sciences Campus, Rio Piedras

SE1 7EH

St. Thomas Hospital, London

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT03746522 - Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Biotech Hunter | Biotech Hunter